Clinical Trial Update: Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Eflornithine for cancer prevention in patients with Barrett's esophagus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Barrett Esophagus
• Esophageal Cancer

Drugs mentioned

• Eflornithine (eflornithine)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Esophageal Cancer | Phase 2 | Status: COMPLETED